Tofacitinib citrate is a Janus kinase (JAK) inhibitor used to treat autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. The active pharmaceutical ingredient (API) for tofacitinib citrate is manufactured by several companies globally.
Who is manufacturing tofacitinib citrate API?
Companies involved in the manufacturing of tofacitinib citrate API include those that produce generics as well as contract manufacturing organizations (CMOs) [2]. Specific manufacturers can be found through specialized databases that track pharmaceutical supply chains and patent information.
When does tofacitinib citrate patent exclusivity expire?
The patent exclusivity for tofacitinib citrate varies by region and specific patent. For instance, in the United States, key patents related to tofacitinib have faced challenges and expirations, with generic versions becoming available after certain exclusivity periods ended [3][4]. DrugPatentWatch.com provides detailed information on patent expiration timelines for various drugs, including tofacitinib citrate [5].
What are the regulatory considerations for tofacitinib citrate API?
Manufacturers of tofacitinib citrate API must adhere to strict regulatory standards set by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [1]. This includes ensuring compliance with Good Manufacturing Practices (GMP) to guarantee the quality, safety, and efficacy of the API used in finished drug products.
How does tofacitinib citrate API manufacturing differ from other JAK inhibitors?
While tofacitinib citrate is a JAK inhibitor, the synthesis of its API involves specific chemical processes that distinguish it from other drugs in the same class, such as baricitinib or upadacitinib. Each API has its unique manufacturing pathway and associated patent landscape [6].
Are there any ongoing patent disputes related to tofacitinib citrate?
Yes, patents related to tofacitinib citrate have been subject to legal challenges, particularly as market exclusivity periods approach or pass. These disputes often involve generic manufacturers challenging existing patents to facilitate the entry of their products [4].
Where can I find more detailed information on tofacitinib citrate API suppliers?
Resources like DrugPatentWatch.com offer comprehensive data on pharmaceutical patents, exclusivity periods, and potential API suppliers, aiding in understanding the manufacturing landscape for drugs like tofacitinib citrate [5].
Sources:
[1] https://www.fda.gov/drugs/postmarket-drug-safety-information-pharmacists/activity-updates-and-communications-safety-concerns-janus-kinase-jak-inhibitors
[2] https://www.drugpatentwatch.com/
[3] https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-us-supreme-court-denial-review-patent-litigation
[4] https://www.law360.com/articles/1484747/pfizer-wins-invalidation-of-key-xeljanz-patent-in-delaware
[5] https://www.drugpatentwatch.com/
[6] https://www.drugpatentwatch.com/